Citius pharmaceuticals achieves primary and secondary endpoints in phase 3 trial of mino-lok antibiotic lock solution

Trial achieves statistically significant primary endpoint (p=0.0006) secondary endpoint demonstrates statistically significant overall success of mino-lok therapy with a greater percentage of patients retaining their catheters (p=0.0025) cranford, n.j. , may 21, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced positive topline results of its pivotal phase 3 clinical trial of mino-lok®, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (clabsi) or catheter-related bloodstream infections (crbsi).
CTXR Ratings Summary
CTXR Quant Ranking